SEQENS Pharmaceutical Solutions (broader group)

Écully, France
Small Molecule API HPAPI Pharmaceutical Intermediates Specialty Ingredients Flow Chemistry Biocatalysis Photochemistry
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: SEQENS Pharmaceutical Solutions (broader group)

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Écully, France
Modalities
Small Molecule API, HPAPI, Pharmaceutical Intermediates, Specialty Ingredients, Flow Chemistry, Biocatalysis, Photochemistry
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About SEQENS Pharmaceutical Solutions (broader group)

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesSmall Molecule API, HPAPI, Pharmaceutical Intermediates, Specialty Ingredients, Flow Chemistry, Biocatalysis, Photochemistry
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (7 modalities)

Frequently Asked Questions About SEQENS Pharmaceutical Solutions (broader group)

What is SEQENS Pharmaceutical Solutions (broader group)'s CDMO Signal Score?
SEQENS Pharmaceutical Solutions (broader group) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating SEQENS Pharmaceutical Solutions (broader group) for a manufacturing program?
Use the free AI matchmaker to compare SEQENS Pharmaceutical Solutions (broader group) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
HPAPI CDMOs →

Similar CDMOs

EUROAPI
Paris, France
Small Molecule API, Microbial Fermentation API, Oligonucleotide, Peptide, HPAPI
Fermion (Orion Group)
Espoo, Finland
Small Molecule API, HPAPI, Semi-solid drug product (creams, gels, ointments), Hormonal products
Veranova
Devens, MA
Small Molecule API, HPAPI, ADC payload/linker, Oligonucleotide, Peptide
Sai Life Sciences
Hyderabad, India
Small Molecule API, Complex Small Molecules, HPAPI, ADC, Peptides, Oligonucleotides, Lipids / LNP, Intermediates, Drug Discovery (CRO)
Cambrex Corporation
East Rutherford, NJ
Small Molecule API, HPAPI, Controlled Substances, Oral Solid Dose, Solid State Research, Particle Engineering, Drug Product (OSD), Controlled Release